Oral Medicine & Oral Pathology Clinic, Montreal General Hospital, Montreal, QC, Canada.
Department of Surgery, City of Hope National Cancer Center, Duarte, CA, USA.
Support Care Cancer. 2024 Mar 5;32(4):212. doi: 10.1007/s00520-024-08388-4.
Medication-related osteonecrosis of the jaw (MRONJ) is a debilitating side effect of antiresorptive and antiangiogenic agents that can lead to progressive bone destruction in the maxillofacial region. Dental surgery, including tooth extractions, commonly trigger the onset of MRONJ. While guidelines suggest avoiding extraction when possible, complete avoidance is not always feasible, as necrosis can develop from dental and periodontal disease without dental procedures. The goal of this article is to provide an update review of current preventive and therapeutic approaches for MRONJ.
A comprehensive electronic search was conducted on PubMed/MEDLINE, Embase, and Scopus databases. All English articles encompassing randomized controlled trials, systematic reviews, observational studies, and case studies were reviewed. The current medical treatments and adjuvant therapies for managing MRONJ patients were critically assessed and summarized.
Pentoxifylline and alpha tocopherol (PENT-E), teriparatide, photobiomodulation (PBM), photodynamic therapy (PDT), and the use of growth factors have shown to enhance healing in MRONJ patients. Implementing these methods alone or in conjunction with surgical treatment has been linked to reduced discomfort and improved wound healing and increased new bone formation.
While several adjuvant treatment modalities exhibit promising results in facilitating the healing process, current clinical practice guidelines predominantly recommend antibiotic therapy as a non-surgical approach, primarily addressing secondary infections in necrotic areas. However, this mainly addresses the potential infectious complication of MRONJ. Medical approaches including PENT-E, teriparatide, PBM, and PDT can result in successful management and should be considered prior to taking a surgical approach. Combined medical management for both preventing and managing MRONJ holds potential for achieving optimal clinical outcomes and avoiding surgical intervention, requiring further validation through larger studies and controlled trials.
抗吸收和抗血管生成药物相关的颌骨坏死(MRONJ)是一种使人虚弱的副作用,可导致颌面部进行性骨破坏。牙科手术,包括拔牙,通常会引发 MRONJ。虽然指南建议在可能的情况下避免拔牙,但并非总是可行,因为坏死可能会因牙齿和牙周疾病而发生,而无需进行牙科手术。本文的目的是提供对 MRONJ 目前预防和治疗方法的最新综述。
对 PubMed/MEDLINE、Embase 和 Scopus 数据库进行了全面的电子检索。综述了所有涵盖随机对照试验、系统评价、观察性研究和病例研究的英文文章。对目前用于治疗 MRONJ 患者的医学治疗和辅助治疗方法进行了批判性评估和总结。
己酮可可碱和α生育酚(PENT-E)、特立帕肽、光生物调节(PBM)、光动力疗法(PDT)和生长因子的应用已显示出可增强 MRONJ 患者的愈合能力。单独或与手术治疗联合使用这些方法与减少不适、改善伤口愈合和增加新骨形成有关。
虽然几种辅助治疗方法在促进愈合过程中显示出有希望的结果,但当前的临床实践指南主要推荐抗生素治疗作为非手术方法,主要针对坏死区域的继发感染。然而,这主要解决了 MRONJ 的潜在感染并发症。包括 PENT-E、特立帕肽、PBM 和 PDT 在内的医学方法可以实现成功的管理,应在考虑手术方法之前考虑。MRONJ 的预防和管理的联合医学管理有潜力实现最佳的临床结果并避免手术干预,需要通过更大的研究和对照试验进一步验证。